ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 569,18
-0,83%
Dow Jones
40 211,72
0,00%
DAX
18 483,31
-0,63%
Brent Oil
83,005
-1,58%
Bitcoin
63 891,60
-1,48%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Intellia Therapeutics Inc (NTLA)

  7. Intellia Therapeutics Inc (NTLA) Actualités

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NTLA
DateHeureSourceTitreSymboleSociété
20/12/201822h18Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:NTLAIntellia Therapeutics Inc
06/12/201813h46Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NTLAIntellia Therapeutics Inc
06/12/201813h30GlobeNewswire Inc.Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional...NASDAQ:NTLAIntellia Therapeutics Inc
08/11/201822h30GlobeNewswire Inc.Intellia Therapeutics to Present at November Healthcare Investor ConferencesNASDAQ:NTLAIntellia Therapeutics Inc
01/11/201823h38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
31/10/201822h59Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:NTLAIntellia Therapeutics Inc
31/10/201814h04Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NTLAIntellia Therapeutics Inc
31/10/201812h30GlobeNewswire Inc.Intellia Therapeutics Announces Third Quarter 2018 Financial Results and Corporate DevelopmentsNASDAQ:NTLAIntellia Therapeutics Inc
30/10/201821h30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2018 Earnings and Corporate DevelopmentsNASDAQ:NTLAIntellia Therapeutics Inc
29/10/201821h30GlobeNewswire Inc.Intellia Therapeutics Names Glenn Goddard as New Chief Financial OfficerNASDAQ:NTLAIntellia Therapeutics Inc
18/10/201814h30GlobeNewswire Inc.Intellia Therapeutics Presents New Data in In Vivo and Ex Vivo Programs at the 26th Annual Congress of the European Society o...NASDAQ:NTLAIntellia Therapeutics Inc
12/10/201823h31Edgar (US Regulatory)Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)NASDAQ:NTLAIntellia Therapeutics Inc
24/09/201814h30GlobeNewswire Inc.Intellia Therapeutics to Present at October Healthcare Investor ConferencesNASDAQ:NTLAIntellia Therapeutics Inc
10/09/201822h30GlobeNewswire Inc.CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding t...NASDAQ:NTLAIntellia Therapeutics Inc
27/08/201814h00GlobeNewswire Inc.Intellia Therapeutics to Present at September Healthcare Investor ConferencesNASDAQ:NTLAIntellia Therapeutics Inc
23/08/201822h01GlobeNewswire Inc.Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome...NASDAQ:NTLAIntellia Therapeutics Inc
23/08/201814h30GlobeNewswire Inc.Intellia Therapeutics to Host Educational Briefing Webinar on Interference Proceedings Relating to CRISPR/Cas9 Genome Editing...NASDAQ:NTLAIntellia Therapeutics Inc
01/08/201813h30GlobeNewswire Inc.Intellia Therapeutics Announces Second Quarter 2018 Financial ResultsNASDAQ:NTLAIntellia Therapeutics Inc
19/06/201815h05GlobeNewswire Inc.CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editi...NASDAQ:NTLAIntellia Therapeutics Inc
17/05/201813h30GlobeNewswire Inc.Intellia Therapeutics Announces WT1 as Its First Cell Therapy Target, Following Presentation of Early Data at the American So...NASDAQ:NTLAIntellia Therapeutics Inc
14/05/201813h30GlobeNewswire Inc.New Scientific Advisors Focused on Cell Therapy in Immuno-Oncology and Autoimmunity Join Intellia TherapeuticsNASDAQ:NTLAIntellia Therapeutics Inc
02/05/201815h09GlobeNewswire Inc.Intellia Therapeutics Announces First Quarter 2018 Financial ResultsNASDAQ:NTLAIntellia Therapeutics Inc
01/05/201813h16Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:NTLAIntellia Therapeutics Inc
23/04/201815h29GlobeNewswire Inc.UPDATE -- Intellia Therapeutics Announces In Vivo and Ex Vivo Data Presentations at the American Society of Gene and Cell The...NASDAQ:NTLAIntellia Therapeutics Inc
23/04/201814h30GlobeNewswire Inc.Intellia Therapeutics Announces In Vivo and Ex Vivo Data Presentations at the American Society of Gene and Cell Therapy 21st ...NASDAQ:NTLAIntellia Therapeutics Inc
17/04/201813h31Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:NTLAIntellia Therapeutics Inc
23/03/201822h30Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:NTLAIntellia Therapeutics Inc
14/03/201813h06Edgar (US Regulatory)Annual Report (10-k)NASDAQ:NTLAIntellia Therapeutics Inc
14/03/201812h30GlobeNewswire Inc.Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial ResultsNASDAQ:NTLAIntellia Therapeutics Inc
28/02/201822h30GlobeNewswire Inc.Intellia Therapeutics to Present at March Healthcare Investor ConferencesNASDAQ:NTLAIntellia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NTLA

Dernières Valeurs Consultées

BIT
P1HXA8
BNP Paribas Issuance
LSE
BRIG
Blackrock Income And Gro...
LSE
HWDC
Hsbc Msci Wl Ch
LSE
FEV
Fidelity European
NASDAQ
AGNC
AGNC Investment
LSE
BRIC
Ishr Bic 50
NASDAQ
COUP
Coupa Software
LSE
WRN
Worthington
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés